Kameswara Rao Badri

Dr. Kameswara Rao Badri


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2021 in Archives of Microbiology
Verified
Journal Article
Closed access
PDF file
AHAnanda Vardhan Hebbani
Ananda Vardhan Hebbani
SPSwetha Pulakuntla
Swetha Pulakuntla
PPPadmavathi Pannuru
Padmavathi Pannuru
SASreelatha Aramgam
Sreelatha Aramgam
KBKameswara Rao Badri
Kameswara Rao Badri
DVDamodara Reddy Vaddi
Damodara Reddy Vaddi

5 May 2024 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
VKVenkateswarlu Reddy Kanu
Venkateswarlu Reddy Kanu
SPSwetha Pulakuntla
Swetha Pulakuntla
GKGouthami Kuruvalli
Gouthami Kuruvalli
SASree Latha Aramgam
Sree Latha Aramgam
SMShakeela Begum Marthadu
Shakeela Begum Marthadu
DVDamodara Reddy Vaddi
Damodara Reddy Vaddi

7 July 2023 in Gene
Verified
Journal Article
Closed access
SMSubhasish Maity
Subhasish Maity
ASAyantika Santra
Ayantika Santra
AHAnanda Vardhan Hebbani
Ananda Vardhan Hebbani
SPSwetha Pulakuntla
Swetha Pulakuntla
ACAnkita Chatterjee
Ankita Chatterjee
DVDamodara Reddy Vaddi
Damodara Reddy Vaddi

1 April 2019 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
PKPeddanna Kotha
Peddanna Kotha
SMSaritha Marella
Saritha Marella
RARajasekhar Allagadda
Rajasekhar Allagadda
KBKameswara Rao Badri
Kameswara Rao Badri
CAChippada Apparao
Chippada Apparao
Anisomeles malabarica (AM) is an aromatic plant traditionally used for the treatment of diabetes mellitus in India. Following bioassay guided fractionation, we recently identified an active fraction of AM (AMAF, with potential mix of active principles) that showed significant antihyperglycemic and antihyperlipidemic activities. In addition, AMAF treatment improved insulin levels. However, the biochemical mechanism/s through which AMAF demonstrates the antidiabetic effects is largely unknown. Based on its beneficial effects we investigated the biochemical mechanism of the anti-diabetic activity of A.malabarica active fraction (AMAF) in streptozotocin (STZ) induced diabetic rats. Streptozotocin induced diabetic rats were treated with AMAF (50 mg AMAF/kg/day) for 30 days and alterations in the body weights, glycogen and protein content of tissues, functional markers of hepatic and renal tissues, carbohydrate metabolic enzymes and their genes expression were evaluated. Lipid peroxides levels and activities of antioxidant enzymes of hepatic and renal tissues were also measured. The AMAF treatment resulted in increase in body weights, hepatic and renal protein and tissue glycogen levels in diabetic treated rats compared to diabetic rats. In addition, the treatment improved activities of carbohydrate metabolic enzymes, antioxidant enzymes and, liver and renal functional markers in the AMAF treated diabetic rats. Gene expressions of key carbohydrate metabolic enzymes/factors glucokinase, glucose transporter protein (GLUT-2) and phosphoenolpyruvate carboxykinase (PEPCK) were also normalized up on AMAF treatment in diabetic rats. Our studies indicate that the isolated active fraction of AM (AMAF) from the leaves of A.malabarica positively regulated the glucose homeostasis and oxidative stress through carbohydrate metabolism and antioxidant enzyme activities respectively in hepatic and renal tissues.

22 July 2021 in Frontiers in Pharmacology
Verified
Journal Article
Open access
RKReddy Sankaran Karunakaran
Reddy Sankaran Karunakaran
OLOruganti Lokanatha
Oruganti Lokanatha
GSGanjayi Muni Swamy
Ganjayi Muni Swamy
CVChintha Venkataramaiah
Chintha Venkataramaiah
MKMuppuru Muni Kesavulu
Muppuru Muni Kesavulu
BMBalaji Meriga
Balaji Meriga
Objective: To evaluate the therapeutic efficacy and underlying molecular mechanisms of Bauhiniastatin-1 (BSTN1) to alleviate adiposity in diet-induced obese rodent model and in 3T3-L1 cells.Methods: BSTN1 was purified and confirmed through HPLC. In-vitro experiments such as MTT assay, Oil Red-O (ORO) stain, cellular lipid content, glycerol release and RT-PCR analysis were performed in 3T3-L1 cells in the presence and absence of BSTN1. In animal experiments, rats were divided into Group-I: normal pellet diet-fed, Group-II: HFD-fed, Groups-III, IV and V: HFD-fed BSTN1 (1.25, 2.5, and 5 mg/kg.b.wt./day/rat)-treated and Group-VI: HFD-fed Orlistat-treated. The rats were fed either normal diet or high fat diet (HFD) for 18 weeks and water ad-libitum. BSTN1 was orally administered from 13th week onwards to the selected HFD-fed groups. Body composition parameters, biochemical assays, histopathology examination and western blot analysis were performed to identify the predicted targets related to obesity. Molecular docking studies threw light on the binding interactions of BSTN1 against PPAR-γ, FAS and AMPK.Results: BSTN1 at 20 μM significantly (p < 0.001) inhibited adipocyte differentiation and lipid accumulation in 3T3-L1 cells. A conspicuous down-regulation in the mRNA expression levels of PPAR-γ, FAS and SREBP1 was observed but AMPK expression remained unchanged in BSTN1 treated 3T3-L1 cells. A substantial decrease in body weight gain, fat percent, total body fat, serum and liver lipid profile (except high-density lipoprotein), glucose, insulin and insulin resistance in BSTN1 treated rats was noticed in a dose dependent manner. In BSTN1 (5 mg/kg.b.wt.)-treated groups significantly (p < 0.01) elevated plasma adiponectin level but reduced leptin level as well as fall in serum AST and ALT were noticed. Further, the disturbed structural integrity and architecture of adipose and hepatic tissues due to high fat diet feeding were considerably recovered with BSTN1 treatment. Down-regulation in the protein expression level of PPAR-γ and activation of AMPK through phosphorylation was observed in BSTN1 treated rats than the untreated. Molecular docking studies revealed strong binding interactions of BSTN1 against PPAR-γ and AMPK and thus supported the experimental results.Conclusion: Taken together, the results suggest that BSTN1 could be a promising pharmacological molecule in the treatment of obesity and dyslipidemia.

1 July 2019 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
SNSha’kAyla Nunez
Sha’kAyla Nunez
CYCorey Young
Corey Young
OAOlayinka Adebayo
Olayinka Adebayo
KMKesavulu Muni Muppuru
Kesavulu Muni Muppuru
KBKameswara Rao Badri
Kameswara Rao Badri